Literature DB >> 13497321

Studies of the bone marrow in immunological granulocytopenia; following administration of salicylazosulfapyridine.

R S EVANS, W P FORD.   

Abstract

Entities:  

Keywords:  AGRANULOCYTOSIS/etiology and pathogenesis; COLITIS, ULCERATIVE/therapy; LEUKOERYTHROBLASTIC/pathology; SULFONAMIDES/injurious effects

Mesh:

Substances:

Year:  1958        PMID: 13497321     DOI: 10.1001/archinte.1958.00260140076012

Source DB:  PubMed          Journal:  AMA Arch Intern Med        ISSN: 0888-2479


× No keyword cloud information.
  8 in total

1.  Sulphasalazine induced agranulocytosis in a patient with rheumatoid arthritis.

Authors:  P T Murphy; J R O'Donnell
Journal:  Ir J Med Sci       Date:  1990-06       Impact factor: 1.568

2.  Salicylazosulfapyridine in inflammatory bowel disease.

Authors:  K M Das; I Sternlieb
Journal:  Am J Dig Dis       Date:  1975-10

Review 3.  Sulfasalazine. Adverse effects and desensitization.

Authors:  S L Taffet; K M Das
Journal:  Dig Dis Sci       Date:  1983-09       Impact factor: 3.199

4.  Direct and metabolism-dependent toxicity of sulphasalazine and its principal metabolites towards human erythrocytes and leucocytes.

Authors:  M Pirmohamed; M D Coleman; F Hussain; A M Breckenridge; B K Park
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

5.  Agranulocytosis associated with sulphasalazine therapy.

Authors:  P Cochrane; P Atkins; S Ehsanullah
Journal:  Postgrad Med J       Date:  1973-09       Impact factor: 2.401

Review 6.  Clinical pharmacokinetics of sulphasalazine.

Authors:  K M Das; R Dubin
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

Review 7.  Drug-induced agranulocytosis.

Authors:  V Pisciotta
Journal:  Drugs       Date:  1978-02       Impact factor: 9.546

Review 8.  On the possible mechanisms and predictability of clozapine-induced agranulocytosis.

Authors:  A V Pisciotta; S A Konings; L L Ciesemier; C E Cronkite; J A Lieberman
Journal:  Drug Saf       Date:  1992       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.